PARACETAMOL 325MG + PHENYLEPHRINE 5MG + CAFFEINE 30MG + DIPHENHYDRAMINE 25MG TABLETS is a multi-component solid oral pharmaceutical formulation containing four active pharmaceutical ingredients in a single tablet. The formulation combines Paracetamol, Phenylephrine, Caffeine, and Diphenhydramine in defined quantities, requiring controlled formulation development to achieve accurate ingredient distribution and consistent finished-product characteristics.
The stated composition contains Paracetamol 325MG, Phenylephrine 5MG, Caffeine 30MG, and Diphenhydramine 25MG. Since the active ingredients are present at different concentrations, the manufacturing process requires particular attention to dispensing accuracy, blend uniformity, particle characteristics, and compression behavior.
The formulation may contain suitable pharmaceutical excipients such as diluents, binders, disintegrants, glidants, lubricants, stabilizers, and other functional ingredients. Their selection depends on the finalized formulation and the desired physical properties of the finished tablet.
Preformulating studies may evaluate particle size, bulk density, flowability, moisture content, compressibility, and compatibility between active ingredients and excipients. These parameters help establish an appropriate manufacturing strategy and support consistent tablet quality.
The development of PARACETAMOL 325MG + PHENYLEPHRINE 5MG + CAFFEINE 30MG + DIPHENHYDRAMINE 25MG TABLETS involves evaluating the individual physicochemical characteristics of all four active ingredients. Differences in particle size, density, flow properties, and concentration can influence the behavior of the final powder blend.
Paracetamol represents the highest quantity in the stated formulation, while Phenylephrine is present at a comparatively lower level. Caffeine and Diphenhydramine occupy intermediate positions within the composition. These differences make uniform distribution an important manufacturing consideration.
Controlled sieving or milling may be performed where necessary to obtain appropriate particle characteristics. Premixing or geometric dilution techniques may be considered for lower-quantity ingredients to improve their distribution within the overall blend.
Compatibility studies may also be performed between the active pharmaceutical ingredients and selected excipients. Such studies can evaluate potential changes in appearance, moisture behavior, chemical stability, or other relevant characteristics.
The blending sequence is established during formulation development. Mixing time, equipment loading, order of addition, and environmental conditions can influence blend uniformity and should therefore be appropriately controlled.
Representative sampling of the blend may be performed to assess homogeneity before compression. This helps verify that the formulation is adequately mixed before proceeding to tablet manufacturing.
Manufacturing begins with the receipt, identification, sampling, testing, and approval of the active pharmaceutical ingredients and excipients. Each material is dispensed according to the approved master manufacturing formula using calibrated equipment.
The ingredients may undergo sieving or other preliminary processing before entering the blending stage. Depending on the powder properties, the formulation may be manufactured through direct compression, dry granulation, or another suitable tablet-production technology.
During blending, the active ingredients are incorporated with the selected excipients under controlled conditions. The objective is to produce a homogeneous powder mixture with suitable flow and compressibility.
If granulation is required, the process parameters are established according to the formulation requirements. Granules are subsequently dried and sized as appropriate before lubrication and compression.
During tablet compression, parameters such as tablet weight, thickness, hardness, compression force, machine speed, and physical appearance are monitored. These controls help maintain consistent tablet characteristics throughout the production batch.
The final tablet should possess adequate mechanical strength for handling, packaging, transportation, and storage. At the same time, formulation and compression parameters are controlled to achieve appropriate disintegration and dissolution characteristics according to the product specification.
In-process checks are performed at defined intervals to identify and correct potential manufacturing variation.
Quality control of PARACETAMOL 325MG + PHENYLEPHRINE 5MG + CAFFEINE 30MG + DIPHENHYDRAMINE 25MG TABLETS involves evaluation of the chemical, physical, and performance characteristics of the finished dosage form.
Finished-product testing may include identification and assay of Paracetamol, Phenylephrine, Caffeine, and Diphenhydramine. Other applicable tests may include related substances, uniformity of dosage units, dissolution, disintegration, average weight, hardness, friability, moisture content, and appearance.
Because four active ingredients are present in the same formulation, analytical methods should be appropriately validated to provide accurate and reliable results for each component. Analytical separation is particularly important where active ingredients may have overlapping detection characteristics.
Uniformity testing helps confirm that individual tablets contain the required proportion of each active ingredient. Representative sampling and appropriate analytical procedures are therefore important parts of the quality-control process.
Physical testing may evaluate tablet dimensions, surface appearance, color consistency, hardness, friability, and other relevant attributes. These characteristics contribute to the overall manufacturing consistency of the finished product.
Quality assurance additionally includes raw-material qualification, equipment calibration, process validation, environmental controls, batch manufacturing records, deviation investigation, change control, and final batch-release procedures.
Stability evaluation is an important component of product development for PARACETAMOL 325MG + PHENYLEPHRINE 5MG + CAFFEINE 30MG + DIPHENHYDRAMINE 25MG TABLETS. The purpose of stability studies is to assess whether the product maintains its specified quality characteristics throughout the proposed shelf life.
Stability samples may be evaluated for appearance, assay, degradation-related parameters, dissolution, moisture content, physical properties, and other relevant quality attributes at predetermined intervals.
Packaging selection is based on the formulation's stability profile and the required level of protection against environmental exposure. Pharmaceutical-grade blister packs, strip packs, or other suitable container-closure systems may be selected according to the approved product configuration.
The packaging should help protect the tablets against moisture, light, mechanical damage, and other factors that could affect product quality. Container-closure compatibility may also be assessed during development.
Packaging operations include controlled tablet counting or feeding, sealing, coding, labeling, and secondary packaging. Fill-count accuracy and seal integrity are monitored to maintain consistency between individual packs.
Batch number, manufacturing information, expiry details, product identification, and other required labeling elements should be incorporated according to applicable regulatory requirements.
PARACETAMOL 325MG + PHENYLEPHRINE 5MG + CAFFEINE 30MG + DIPHENHYDRAMINE 25MG TABLETS can form part of a diversified pharmaceutical product portfolio containing combination tablets, capsules, syrups, suspensions, drops, creams, and other dosage forms. Multi-component tablets require systematic control of raw materials, formulation parameters, blending, compression, analytical testing, and packaging.
A structured pharmaceutical manufacturing system involves formulation-development specialists, production teams, quality-control laboratories, quality-assurance personnel, packaging departments, and regulatory professionals. Coordination between these functions helps maintain standardized product specifications.
For combination formulations containing ingredients at different strengths, accurate dispensing and blend uniformity are especially important. Appropriate analytical methods further support reliable quality assessment of every active component.
For companies expanding their PCD Pharma Franchise portfolio, this four-component tablet can be incorporated into a broader and professionally organized pharmaceutical range. Consistent manufacturing, validated analytical testing, stability evaluation, suitable packaging, and controlled documentation can support the development of a reliable pharmaceutical product portfolio for organized distribution and long-term business growth.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech